{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:40:38Z","timestamp":1790052038771,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T00:00:00Z","timestamp":1532131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"The Inger and John Fredriksen Foundation for Ovarian Cancer Research","award":["None"],"award-info":[{"award-number":["None"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00428-018-2418-x","type":"journal-article","created":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T05:59:16Z","timestamp":1532152756000},"page":"463-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma"],"prefix":"10.1007","volume":"473","author":[{"given":"Hadil","family":"Onallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liora Jacobs","family":"Catane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes G.","family":"Trop\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea E.","family":"Hetland Falkenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuven","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-8427","authenticated-orcid":false,"given":"Ben","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,21]]},"reference":[{"key":"2418_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87\u2013108","journal-title":"CA Cancer J Clin"},{"key":"2418_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1586\/14737159.2016.1156532","volume":"16","author":"B Davidson","year":"2016","unstructured":"Davidson B (2016) Recently identified drug resistance biomarkers in ovarian cancer. Expert Rev Mol Diagn 16:569\u2013578","journal-title":"Expert Rev Mol Diagn"},{"key":"2418_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.bbalip.2008.06.005","volume":"1781","author":"J Aoki","year":"2008","unstructured":"Aoki J, Inoue A, Okudaira S (2008) Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 1781:513\u2013518","journal-title":"Biochim Biophys Acta"},{"key":"2418_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jama.280.8.719","volume":"280","author":"Y Xu","year":"1998","unstructured":"Xu Y, Shen Z, Wiper DW et al (1998) Lysophosphatidic acid as a potential marker for ovarian and other gynecologic cancers. JAMA 280:719\u2013723","journal-title":"JAMA"},{"key":"2418_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/1947601911419362","volume":"2","author":"ZG Goldsmith","year":"2011","unstructured":"Goldsmith ZG, Ha JH, Jayaraman M, Dhanasekaran DN (2011) Lysophosphatidic acid stimulates the proliferation of ovarian cancer cells via the gep proto-oncogene G\u03b1(12). Genes Cancer 2:563\u2013575","journal-title":"Genes Cancer"},{"key":"2418_CR6","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.biochi.2010.04.015","volume":"92","author":"S Okudaira","year":"2010","unstructured":"Okudaira S, Yukiura H, Aoki J (2010) Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 92:698\u2013706","journal-title":"Biochimie"},{"key":"2418_CR7","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1194\/jlr.R046458","volume":"55","author":"YC Yung","year":"2014","unstructured":"Yung YC, Stoddard NC, Chun J (2014) LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res 55:1192\u20131214","journal-title":"J Lipid Res"},{"key":"2418_CR8","doi-asserted-by":"publisher","first-page":"e5583","DOI":"10.1371\/journal.pone.0005583","volume":"4","author":"MM Murph","year":"2009","unstructured":"Murph MM, Liu W, Yu S et al (2009) Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One 4:e5583","journal-title":"PLoS One"},{"key":"2418_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1476-5381.2010.00815.x","volume":"161","author":"G Tigyi","year":"2010","unstructured":"Tigyi G (2010) Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 161:241\u2013270","journal-title":"Br J Pharmacol"},{"key":"2418_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.canlet.2014.09.030","volume":"356","author":"JD Ward","year":"2015","unstructured":"Ward JD, Ha JH, Jayaraman M, Dhanasekaran DN (2015) LPA-mediated migration of ovarian cancer cells involves translocalization of G\u03b1i2 to invadopodia and association with Src and \u03b2-pix. Cancer Lett 356:382\u2013391","journal-title":"Cancer Lett"},{"key":"2418_CR11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/jnci\/djn378","volume":"100","author":"S Yu","year":"2008","unstructured":"Yu S, Murph MM, Lu Y et al (2008) Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100:1630\u20131642","journal-title":"J Natl Cancer Inst"},{"key":"2418_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DS, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13:273\u2013282","journal-title":"Nat Rev Cancer"},{"key":"2418_CR13","first-page":"483","volume":"6","author":"CQ Bai","year":"2014","unstructured":"Bai CQ, Yao YW, Liu CH et al (2014) Diagnostic and prognostic significance of lysophosphatidic acid in malignant pleural effusions. J Thorac Dis 6:483\u2013490","journal-title":"J Thorac Dis"},{"key":"2418_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1096\/fj.14-262659","volume":"29","author":"G Venkatraman","year":"2015","unstructured":"Venkatraman G, Benesch MG, Tang X, Dewald J, McMullen TP, Brindley DN (2015) Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment. FASEB J 29:772\u2013785","journal-title":"FASEB J"},{"key":"2418_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3858\/emm.2008.40.6.607","volume":"40","author":"KJ Jeong","year":"2008","unstructured":"Jeong KJ, Park SY, Seo JH et al (2008) Lysophosphatidic acid receptor 2 and Gi\/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp Mol Med 40:607\u2013616","journal-title":"Exp Mol Med"},{"key":"2418_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1042\/BST20110608","volume":"40","author":"M Gotoh","year":"2012","unstructured":"Gotoh M, Fujiwara Y, Yue J et al (2012) Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans 40:31\u201336","journal-title":"Biochem Soc Trans"},{"key":"2418_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/boc.201300011","volume":"105","author":"S Willier","year":"2013","unstructured":"Willier S, Butt E, Grunewald TG (2013) Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol Cell 105:317\u2013333","journal-title":"Biol Cell"},{"key":"2418_CR18","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.4161\/cc.8.22.9937","volume":"8","author":"S Liu","year":"2009","unstructured":"Liu S, Murph M, Panupinthu N, Mills GB (2009) ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 8:3695\u20133701","journal-title":"Cell Cycle"},{"key":"2418_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.bone.2011.12.002","volume":"50","author":"J Blackburn","year":"2012","unstructured":"Blackburn J, Mansell JP (2012) The emerging role of lysophosphatidic acid (LPA) in skeletal biology. Bone 50:756\u2013762","journal-title":"Bone"},{"key":"2418_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3109\/10799893.2013.876042","volume":"34","author":"T Tsujiuchi","year":"2014","unstructured":"Tsujiuchi T, Hirane M, Dong Y, Fukushima N (2014) Diverse effects of LPA receptors on cell motile activities of cancer cells. J Recept Signal Transduct Res 34:149\u2013153","journal-title":"J Recept Signal Transduct Res"},{"key":"2418_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1023\/A:1008217129273","volume":"9","author":"AM Westermann","year":"1998","unstructured":"Westermann AM, Havik E, Postma FR et al (1998) Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 9:437\u2013442","journal-title":"Ann Oncol"},{"key":"2418_CR22","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/1947601913475360","volume":"3","author":"JD Ward","year":"2012","unstructured":"Ward JD, Dhanasekaran DN (2012) LPA stimulates the phosphorylation of p130Cas via G\u03b1i2 in ovarian cancer cells. Genes Cancer 3:578\u2013591","journal-title":"Genes Cancer"},{"key":"2418_CR23","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2013","unstructured":"Lengyel E (2013) Ovarian cancer development and metastasis. Am J Pathol 177:1053\u20131064","journal-title":"Am J Pathol"},{"key":"2418_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fonc.2013.00256","volume":"3","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Stenvers KL (2013) Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol 3:256","journal-title":"Front Oncol"},{"key":"2418_CR25","volume-title":"Serous effusions","year":"2018","unstructured":"Davidson B, Firat P, Michael CW (eds) (2018) Serous effusions, 2nd edn. Springer, London","edition":"2"},{"key":"2418_CR26","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3892\/ol.2014.1926","volume":"7","author":"H Wang","year":"2014","unstructured":"Wang H, Liu W, Wei D, Hu K, Wu X, Yao Y (2014) Effect of the LPA-mediated CXCL12-CXCR4 axis in the tumor proliferation, migration and invasion of ovarian cancer cell lines. Oncol Lett 7:1581\u20131585","journal-title":"Oncol Lett"},{"key":"2418_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0304-3835(02)00713-9","volume":"192","author":"T Fujita","year":"2003","unstructured":"Fujita T, Miyamoto S, Onoyama I, Sonoda K, Mekada E, Nakano H (2003) Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett 192:161\u2013169","journal-title":"Cancer Lett"},{"key":"2418_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ygyno.2006.10.016","volume":"104","author":"P Wang","year":"2007","unstructured":"Wang P, Wu X, Chen W, Liu J, Wang X (2007) The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol Oncol 104:714\u2013720","journal-title":"Gynecol Oncol"},{"key":"2418_CR29","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1186\/s12885-016-2865-1","volume":"16","author":"X Yu","year":"2016","unstructured":"Yu X, Zhang Y, Chen H (2016) LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study. BMC Cancer 16:846","journal-title":"BMC Cancer"},{"key":"2418_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/stem.2279","volume":"34","author":"EJ Seo","year":"2016","unstructured":"Seo EJ, Kwon YW, Jang IH et al (2016) Autotaxin regulates maintenance of ovarian cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism. Stem Cells 34:551\u2013564","journal-title":"Stem Cells"},{"key":"2418_CR31","doi-asserted-by":"publisher","first-page":"9643","DOI":"10.1073\/pnas.0600979103","volume":"103","author":"A Boucharaba","year":"2006","unstructured":"Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Cl\u00e9zardin P, Peyruchaud O (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 103:9643\u20139648","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2418_CR32","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.lfs.2006.12.041","volume":"80","author":"A Tokumura","year":"2007","unstructured":"Tokumura A, Kume T, Fukuzawa K et al (2007) Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity. Life Sci 80:1641\u20131649","journal-title":"Life Sci"},{"key":"2418_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0076-6879(07)33001-2","volume":"433","author":"M Murph","year":"2007","unstructured":"Murph M, Tanaka T, Pang J et al (2007) Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol 433:1\u201325","journal-title":"Methods Enzymol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-018-2418-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T19:29:16Z","timestamp":1563650956000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-018-2418-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,21]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["2418"],"URL":"https:\/\/doi.org\/10.1007\/s00428-018-2418-x","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,21]]},"assertion":[{"value":"30 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Regional Committee for Medical Research Ethics in Norway.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}